We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

US FDA snubs Merck's ezetimibe/atorvastatin combo statin pill

News

Executive Summary

Merck failed to convince the US FDA to approve the pharma giant's ezetimibe-atorvastatin combo statin pill, known as MK-0653C, as a treatment for primary or mixed hyperlipidemia, the company revealed on 5 March, noting that regulators said additional data will be needed before the experimental medication can enter the marketplace.